全球SARS-CoV-2基因组中与molnupiravir相关的突变特征
Theo Sanderson1, Ryan Hisner2, I'ah Donovan-Banfield3,4
1Francis Crick Institute, London, UK. theo.sanderson@crick.ac.uk.
Nature
|September 25, 2023
概括
抗病毒药物Molnupiravir可以导致SARS-CoV-2的突变. 这项研究发现了molnupiravir诱导的病毒突变的证据,突变菌株的潜在传播.
科学领域:
- 病毒学
- 基因组学
- 流行病学
背景情况:
- 莫尔努皮拉维尔是一种用于治疗SARS-CoV-2感染的抗病毒药物.
- 它通过引入病毒基因组中的突变来起作用,旨在降低病毒载量.
- 如果感染未完全清除,可能会传播突变病毒.
研究的目的:
- 调查 SARS-CoV-2 中摩尔努皮拉维尔诱导的突变发生的证据.
- 鉴定和描述与molnupiravir治疗相关的特定突变特征.
- 评估莫尔努皮拉维尔突变的SARS-CoV-2谱系的进一步传播潜力.
主要方法:
- 对SARS-CoV-2测序数据库的系统分析.
- 识别具有高比例G-to-A和C-to-T突变的遗传分支.
- 从molnupiravir治疗患者的病毒中分析突变光谱.
- 与治疗记录和地理/人口数据的相关性.
主要成果:
- 在SARS-CoV-2测序数据中发现了大量molnupiravir变异的证据.
- 在2022年主要观察到具有G-to-A和C-to-T突变的特定长基因分支,与molnupiravir的使用相吻合.
- 鉴定出一种与molnupiravir治疗相匹配的突变谱,有进一步传播的证据.
- 在高G-to-A突变分支与molnupiravir使用之间确实存在直接关联.
结论:
- 摩尔努皮拉维尔治疗在SARS-CoV-2中留下可检测的突变特征.
- 突变的SARS-CoV-2血统可以传递,携带着molnupiravir突变的特征.
- 这些发现强调了在抗病毒治疗期间监测病毒演变的重要性.
相关概念视频
Viral Mutations
32.4K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.4K
Single Nucleotide Polymorphisms-SNPs
15.2K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.2K


